MX2024009960A - Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes. - Google Patents

Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes.

Info

Publication number
MX2024009960A
MX2024009960A MX2024009960A MX2024009960A MX2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A MX 2024009960 A MX2024009960 A MX 2024009960A
Authority
MX
Mexico
Prior art keywords
kir3dl3
inhibitors
immune cell
cell activating
activating agents
Prior art date
Application number
MX2024009960A
Other languages
English (en)
Spanish (es)
Inventor
Scott Chappel
Detlev Biniszkiewicz
Bijan Etemad-Gilbertson
Original Assignee
Nextpoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nextpoint Therapeutics Inc filed Critical Nextpoint Therapeutics Inc
Publication of MX2024009960A publication Critical patent/MX2024009960A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/15Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31Chimeric antigen receptors [CAR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0646Natural killers cells [NK], NKT cells
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/16Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226Class 2 CAS enzyme complex, e.g. single CAS protein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024009960A 2022-02-22 2023-02-21 Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes. MX2024009960A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263312507P 2022-02-22 2022-02-22
US202263418105P 2022-10-21 2022-10-21
PCT/US2023/013537 WO2023163956A2 (en) 2022-02-22 2023-02-21 Kir3dl3 inhibitors and immune cell activating agents

Publications (1)

Publication Number Publication Date
MX2024009960A true MX2024009960A (es) 2024-08-26

Family

ID=87766832

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009960A MX2024009960A (es) 2022-02-22 2023-02-21 Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes.

Country Status (9)

Country Link
US (1) US20250171533A1 (https=)
EP (1) EP4482526A4 (https=)
JP (1) JP2025506731A (https=)
KR (1) KR20250005988A (https=)
AU (1) AU2023225596A1 (https=)
CA (1) CA3243330A1 (https=)
IL (1) IL314839A (https=)
MX (1) MX2024009960A (https=)
WO (1) WO2023163956A2 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992551A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
DK3515478T3 (da) * 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
JP7716393B2 (ja) * 2019-10-04 2025-07-31 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 抗kir3dl3抗体およびそれらの使用
IL291897A (en) * 2019-10-04 2022-06-01 Albert Einstein College Medicine Kir3dl3 inhibitory receptor of the immune system and its uses

Also Published As

Publication number Publication date
JP2025506731A (ja) 2025-03-13
US20250171533A1 (en) 2025-05-29
CA3243330A1 (en) 2023-08-31
KR20250005988A (ko) 2025-01-10
WO2023163956A3 (en) 2024-03-14
EP4482526A4 (en) 2026-04-08
AU2023225596A1 (en) 2024-08-08
EP4482526A2 (en) 2025-01-01
WO2023163956A2 (en) 2023-08-31
IL314839A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
WO2020168300A8 (en) Modified natural killer (nk) cells for immunotherapy
PH12022500020A1 (en) Antibodies against sars-cov-2
WO2018234793A3 (en) Antibodies
WO2022109339A8 (en) Use of dextramer in single cell analysis
MX2024015844A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
ZA202309516B (en) Anti-ccr8 antibodies
EP4410986A3 (en) Cells, vertebrates, populations & methods
MX2022015823A (es) Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
PH12022550373A1 (en) Ex vivo gamma delta t cell populations
PH12017501748A1 (en) Antibodies to icos
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
ZA202205927B (en) Anti-yellow fever virus antibodies, and methods of their generation and use
WO2018120843A9 (zh) 一种三功能分子及其应用
PH12021551475A1 (en) Heterodimeric proteins for modulating gamma delta t cells
CA3207182A1 (en) T cell therapy
ZA202305072B (en) Cd1a antibodies and uses thereof
JOP20220320B1 (ar) أجسام مضادة لـ pd-1
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
WO2020232141A3 (en) Compositions and methods for treating t cell exhaustion
AU2019356414A8 (en) Binding proteins specific for HA-1H and uses thereof
NZ741573A (en) Anti-cd43 antibody and use thereof for cancer treatment
MX2024009960A (es) Inhibidores de receptor similar a la inmunoglobulina de celulas asesinas humanas, tres dominios de inmunoglobulina y cola citoplasmatica larga 3 (kir3dl3) y agentes activadores de celulas inmunes.
WO2023010065A3 (en) Compositions and methods for anti-pacap antibodies
WO2022221844A3 (en) Improved chimeric antigen receptors and uses thereof
WO2021203061A8 (en) Stem cell immunomodulatory therapy for covid-19 infection